

Form PTO-1449

Docket Number 554792000401

Application Number 10/674,684

INFORMATION DISCLOSURE CITATION
IN AN APPLICATION

Applicant

Allan I. Bain et al.

(Use several sheets if necessary)

Filing Date September 29, 2003

Group Art Unit 1626

Mailing Date October 28, 2004

U.S. PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Filing Date If Appropriate
RB	1.	9/27/60	2,954,380	Shapiro et al.	1	1	
RB	2.	11/16/95	3,218,328	Shapiro et al.	1	1	
RB	3.	3/20/79	4,145,435	Szmuszkowicz	1	1	
RB	4.	12/18/79	4,179,501	Szmuszkowicz	1	1	
RB	5.	7/1/86	4,598,087	Horwell	1	1	
RB	6.	4/7/87	4,656,182	Horwell	1	1	
RB	7.	5/5/87	4,663,343	Horwell et al.	1	1	
RB	8.	8/8/89	4,855,316	Horwell et al.	1	1	
RB	9.	11/14/89	4,880,800	Wallis	1	1	
RB	10.	3/6/90	4,906,655	Horwell et al.	1	1	
RB	11.	5/28/91	5,019,588	Horwell et al.	1	1	
RB	12.	9/24/91	5,051,428	Horwell et al.	1	1	
RB	13.	10/22/91	5,059,620	Stout et al.	1	1	
RB	14.	2/20/96	5,492,825	Jan et al.	1	1	
RB	15.	4/9/96	5,506,257	MacLeod et al.	1	1	
RB	16.	6/10/97	5,637,583	MacLeod et al.	1	1	
RB	17.	9/23/97	5,670,335	Jan et al.	1	1	
RB	18.	3/17/98	5,728,535	Lester et al.	1	1	
RB	19.	3/31/98	5,734,021	Lester et al.	1	1	
RB	20.	5/12/98	5,750,537	Nomura et al.	1	1	
RB	21.	10/6/98	5,817,698	Brown et al.	1	1	
RB	22.	3/23/99	5,885,984	MacLeod et al.	1	1	
RB	23.	1/16/01	6,174,879	MacLeod et al.	1	1	
RB	24.	1/30/01	6,180,632	Myers et al.	1	1	

EXAMINER:

DATE CONSIDERED:

3/18/05

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Form PTO-1449	Docket Number 554792000401	Application Number 10/674,684
INFORMATION DISCLOSURE CITATION IN AN APPLICATION	Applicant Allan I. Bain et al.	
(Use several sheets if necessary)	Filing Date September 29, 2003	Group Art Unit 1626
Mailing Date October 28, 2004		

FOREIGN PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Country	Class	Subclass	Translation YES NO
Rb	25.	9/30/93	WO 93/19056	PCT	/	/	
Rb	26.	4/14/94	WO 94/07843	PCT	/	/	
Rb	27.	7/7/94	WO 94/14435	PCT	/	/	
Rb	28.	3/30/95	WO 95/08544	PCT	/	/	
Rb	29.	10/26/95	WO 95/28155	PCT	/	/	
Rb	30.	6/20/96	WO 96/18615	PCT	/	/	
Rb	31.	8/8/96	WO 96/23894	PCT	/	/	
Rb	32.	9/12/97	WO 97/32857	PCT	/	/	
Rb	33.	12/31/97	WO 97/49680	PCT	/	/	
Rb	34.	1/21/99	WO 99/02159	PCT	/	/	
Rb	35.	1/28/99	WO 99/03468	PCT	/	/	
Rb	36.	3/11/99	WO 99/11252	PCT	/	/	
Rb	37.	4/8/99	WO 99/16431	PCT	/	/	
Rb	38.	10/7/99	WO 99/50205	PCT	/	/	
Rb	39.	10/7/99	WO 99/50225	PCT	/	/	
Rb	40.	12/24/03	WO 03/105756	PCT	/	/	
Rb	41.	4/5/88	1234808	CA	/	/	
Rb	42.	4/12/88	1235122	CA	/	/	
Rb	43.	6/6/90	2004575	CA	/	/	
Rb	44.	12/23/97	2008391	CA	/	/	
Rb	45.	6/28/93	2058502	CA	/	/	
Rb	46.	3/20/01	2132841	CA	/	/	
Rb	47.	3/30/95	2172513	CA	/	/	
Rb	48.	9/12/97	2240728	CA	/	/	
Rb	49.	1/28/99	2289055	CA	/	/	
Rb	50.	6/6/74	DE 2 259 260	DE	/	/	No
Rb	51.	7/6/78	DE 2 658 401 (English Abstract)	DE	/	/	No

EXAMINER:

Leber Anderson

DATE CONSIDERED:

3/18/05

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Form PTO-1449	Docket Number 554792000401	Application Number 10/674,684
INFORMATION DISCLOSURE CITATION IN AN APPLICATION	Applicant Allan I. Bain et al.	
(Use several sheets if necessary)	Filing Date September 29, 2003	Group Art Unit 1626
	Mailing Date October 28, 2004	

<i>Rb</i>	52.	12/12/85	DE 3 517 901 (English Abstract)	DE	—	—	No
<i>Rb</i>	53.	5/20/87	0222533 A1	EP	—	—	
<i>Rb</i>	54.	8/1/90	0380063 A1/ B1	EP	—	—	
<i>Rb</i>	55.	7/3/85	0147085 A2/B1	EP	—	—	
<i>Rb</i>	56.	12/19/01	0720605 B1	EP	—	—	
<i>Rb</i>	57.	6/13/90	0372466 A2/A3	EP	—	—	
<i>Rb</i>	58.	7/28/93	0552386 A1	EP	—	—	
<i>Rb</i>	59.	2/28/98	HU 215963 B	HU	—	—	No
<i>Rb</i>	60.	11/5/90	JP 02-270864 (English Abstract)	JP	—	—	No


OTHER DOCUMENTS (including author, title, Date, Pertinent Pages, Etc.)

Examiner Initials	Ref. No.	Title
<i>Rb</i>	61.	Adcock, J.J. et al., (2003) "RSD931, a novel anti-tussive agent acting on airway sensory nerves" Br J Pharm, 138:407-416
<i>Rb</i>	62.	Altria, Kevin D. et al., (2001) "Capillary Electrophoresis as a Routine Analytical Tool in Pharmaceutical Analysis" LCGC 19(9): 972-985
<i>Rb</i>	63.	Amin, et al., (1996) "RPR 101821, a New Potent Cholesterol-lowering Agent: Inhibition of Squalene Synthase and 7-Dehydrocholesterol Reductase", Naunyn-Schmiedeberg's Arch Pharmacol 353:233-240
<i>Rb</i>	64.	Bain, et al., (1997) "Better Antiarrhythmics? Development of Antiarrhythmic Drugs Selective for Ischaemia-Dependent Arrhythmias", Drug Development Research 42:198-210
<i>Rb</i>	65.	Barrett, T.D. (2000) "Ischaemia selectivity confers efficacy for suppression of ischaemia-induced arrhythmias in rats" Eur J Pharm, 398:365-374
<i>Rb</i>	66.	Barrett, T. D. et al., (1997) "A model of myocardial ischemia for the simultaneous assessment of electrophysiological changes and arrhythmias in intact rabbits" J Pharmacol Toxicol Methods, 37:27-36
<i>Rb</i>	67.	Barrett, T.D. et al., (1996) "Atypical Dose Response curves for Antiarrhythmic Drugs"


EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Form PTO-1449		Docket Number 554792000401	Application Number 10/674,684
INFORMATION DISCLOSURE CITATION IN AN APPLICATION		Applicant Allan I. Bain et al.	
(Use several sheets if necessary)		Filing Date September 29, 2003	Group Art Unit 1626
		Mailing Date	October 28, 2004
BPS Proceedings 115P.			
72A	68.	Barrett, T. D. et al., (1996) "Glibenclamide Possesses Transient, Ischaemia Selective Class III Antiarrhythmic Actions But does not Prevent Ischaemic Arrhythmias" BPS Proceedings 116P	
72B	69.	Barrett, Terrance D. (1997) "Ischemia Selective Electrophysiological and antiarrhythmic actions of RSD1019 in ischemic cardiac tissue" J Mol Cell Cardiol, pp 197	
72C	70.	Barrett, Terrance D. et al., (2000) "RSD 1019 suppresses ischaemia-induced monophasic action potential shortening and arrhythmias in anaesthetized rabbits" Br J Pharm, 131:405-414	
72D	71.	Beatch, et al., (2002) "Selectively Prolongs Atrial Refractoriness and Terminates AF in Dogs with Electrically Remodeled Atria", (NASPE) North Amer. Soc. of Pacing & Electrophysiol. 24:698 (Abstract 702)	
72E	72.	Beatch, G. et al., "Effect of a Novel Anti-tussive Compound CP1 Against Citric Acid Induced Cough in Guinea-Pigs" Proc West Pharmacol Soc 20	
72F	73.	Beatch, G. et al., (2003) "Electrophysiological Profile of RSD1235, A New Drug for Conversion of Atrial Fibrillation" Abstracts from AHA Circulation ISSN 0009-7322.	
72G	74.	Beatch, G. et al., "RSD1235 Rapidly and Effectively Terminates Atrial Fibrillation" Abstract submission ESC Congress August 30-September 3, 2003, in Vienna, Austria	
72H	75.	Beatch, G.N. et al., (1996) "Antihistamine-induced Ventricular Arrhythmias" BPS Proceedings 120P	
72I	76.	Beatch, G.N. et al., (1997) "Characterization of a Non-Human Primate Model of Drug-Induced Torsades De Pointes" Proc. West. Pharmacol. Soc., 40: 13-16	
72J	77.	Beatch, G. N. et al., "RSD1235, A Novel Atrial-Selective Antiarrhythmic Drug, Shows Rapid and Extensive Oral Absorption in Man" 12 th International Congress on Cardiovascular Pharmacotherapy, May 7-10, 2003, Barcelona, Spain	
72K	78.	Beatch, G.N. et al., (2002) "RSD1235 Selectively Prolongs Atrial Refractoriness and Terminates AF in Dogs with Electrically Remodeled Atria" PACE 24(Part II):698. Abstract 702	
EXAMINER: 		DATE CONSIDERED: 3/18/05	
EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.			

* no date provided on 1449 or on reference (72)

Form PTO-1449		Docket Number 554792000401	Application Number 10/674,684
INFORMATION DISCLOSURE CITATION IN AN APPLICATION		Applicant Allan I. Bain et al.	
(Use several sheets if necessary)		Filing Date September 29, 2003	Group Art Unit 1626
		Mailing Date October 28, 2004	
Rb	79.	Beatch, G. N. et al., (2002) "Ventricular Fibrillation, and Uncontrolled Arrhythmia Seeking New Targets" Drug Develop Res 55:45-52	
Rb	80.	Bian, et al., (1998) "Effects of K-opioid receptor stimulation in the heart and the involvement of protein kinase C" Brit. J. Pharmacol. 124:600-606	
Rb	81.	Billman, (2003) "RSD-1235", Current Opinion Investigational Drugs 4(3):352-354	
Rb	82.	Boiadjev, et al., (1996) "pH-Sensitive Exciton Chirality Chromophore..Solvatochromic Effects on Circular Dichroism Spectra", Tetrahedron: Asymmetry 7(10):2825-2832	
Rb	83.	Bowen, et al., (1992) "Characterization of the enantiomers of cis-n-[2-(3,4-Dichlorophenyl)Ethyl]-N-Methyl-2-(1-Pyrrolidinyl)Cyclohexylamine (BD737 and BD738): Novel Compounds with High Affinity, Selectivity and Biological Efficacy at Sigma Receptors" J. Pharmacol. Exp. Ther. 262(1):32-40	
Rb	84.	Cardiome Drug Effective for Heart Patients. Press Release, September 3, 2002, 3 pages	
Rb	85.	Cardiome Pharma Corp. Healthcare (Underweight) Company Report December 12, 2002. 26 pages	
Rb	86.	Cardiome Pharma Completes Phase I Safety Study. New Release Transmitted By CNN Newswire, July 30, 2001. 2 pages	
Rb	87.	Cardiome Reports Dosing of First Patient in Pivotal Phase II Study. Press Release January 17, 2002. 3 pages	
Rb	88.	Cardiome Reports Oral Absorption of RSD1235 in Humans. News Release via Canada Newswire (2002). 3 pages	
Rb	89.	Clohs, L. et al., (2002) "Validation of a capillary electrophoresis assay for assessing the metabolic stability of verapamil in human liver microsomes" J Cap Elec & Microchip Tech. 007: 113-117	
Rb	90.	Clohs, Lilian. "Bio-Analytical Applications of Capillary Electrophoresis In A Drug Discovery Setting". CSC Seminar June 2002, 29 pages	
Rb	91.	Clohs, Lilian "Capillary Electrophoresis And Its Applications In The Pharmaceutical Industry" Short Course: One Platform Fits Many Applications. CSC 2002 Short Course, 52 pages	
EXAMINER: 		DATE CONSIDERED: 3/18/05	
EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.			

Form PTO-1449		Docket Number 554792000401	Application Number 10/674,684
INFORMATION DISCLOSURE CITATION IN AN APPLICATION		Applicant Allan I. Bain et al.	
(Use several sheets if necessary)		Filing Date September 29, 2003	Group Art Unit 1626
		Mailing Date	October 28, 2004
Rb	92.	Clohs, Lilian "Capillary Electrophoresis as an Analytical Tool in the Drug Discovery Process" Presentation CE Symposium, August, 2000, 40 pages	
Rb	93.	Clohs, Lilian et al., (2002) "CE Analysis of Propranolol in Human Serum Using Dynamic Capillary Coating" CE Currents: LCGC Europe, Reader Service 14, pp: 289-293	
Rb	94.	Clohs, Lilian. "CE and Drug Metabolism Studies: A Powerful Combination in Drug Discovery" CE Symposium Washington, DC, (August 2002), 31 pages	
Rb	95.	Clohs, Lilian (2001) "Pharmacokinetics profiling of new drug candidates: a key process in drug discovery" 4(1): 6	
Rb	96.	Clohs, Lilian "The Versatility of CE for Drug Pharmacokinetics and Metabolism Studies" Presentation CE Symposium, August, 2001, 46 pages	
Rb	97.	Crotti, et al., (1998) "Regiochemical control of the ring-opening of epoxides by means of chelating processes Part 13...", Chemical Abstracts 129(17):662-663, abstract no. 216472k	
Rb	98.	Crotti, et al., (1998) "Synthesis and Ring-Opening Reactions of the Diastereoisomeric <i>cis</i> - and <i>trans</i> -Epoxides Derived from 3-(Benzyloxy)cyclopentene and 2-(Benzyloxy)-2,5-dihydrofuran" Eur. J. Org. Chem. 8:1675-1686	
Rb	99.	De Costa, Brian R. (1990) "Synthesis and Evaluation of N-Substituted <i>cis</i> -N-Methyl-2-(1-pyrrolidinyl)cyclohexylamines as High Affinity σ Receptor Ligands. Identification of a New Class of Highly Potent and Selective σ Receptor Probes" J Med Chem, 33:3100-3110	
	100.	Doci, A. "Local Anesthetic Effects of Intradermal RSD921 In Healthy Subjects" Clin Pharm & Therapeutics, 65(2): 177	
Rb	101.	Duan, D. et al., (1993) "Potassium Channel Blocking Properties of Propafenone in Rabbit Atrial Myocytes" J Pharm Exp Ther 264(3): 1113-1123	
Rb	102.	Ezrin, Alan M. et al., (2002) "A Dose-Ranging Study of RSD1235, A Novel Antiarrhythmic Agent, In Healthy Volunteers" Pharmacologist, 44(2) (Supplement I), A15: XIV th World Congress of Pharmacology: Meeting Abstracts	
Rb	103.	Ezrin, et al., (2002) "P297 Safety and Pharmacokinetics of RSD1235, a Novel Atrial Fibrillation Converting Drug, in Health Volunteers", Abstracts: 11 th Int. Congress	
EXAMINER: <i>Elaine Anderson</i>		DATE CONSIDERED: 3/18/05	
EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.			

* no date provided on 1449 or on reference (100)

Form PTO-1449		Docket Number 554792000401	Application Number 10/674,684
INFORMATION DISCLOSURE CITATION IN AN APPLICATION		Applicant Allan I. Bain et al.	
(Use several sheets if necessary)		Filing Date September 29, 2003	Group Art Unit 1626
		Mailing Date	October 28, 2004
Cardiovasc. Pharmacother. 16 Abstract P297			
Re	104.	Ezrin, Alan et al., (2002) "Safety and Pharmacokinetics of RSD1235, A novel Atrial Fibrillation Converting Drug, In Healthy Volunteers & Statins Benefit Coronary Heart Disease Patients more than Hypercholesterolaemic Subjects: Inferences Bases on NNT" Poster Int Soc Cardio Pharm, pp 49	
Re	105.	Fedida, D. et al., (2002) "Kv1.5 is an Important Component of Repolarizing K ⁺ Current in Canine Atrial Myocytes" Circulation Research Peer Review Plus Manuscript PDF, 38 pages	
Re	106.	Fedida D. et al. "Kv1.5 channels contribute to canine atrial repolarization." Circulation 2003 in press, (accepted for presentation at AHA Scientific Sessions, November. 8-12, 2003, Orlando, FL). Circulation 2003, v108, p1386	
	107.	Franciosi, Luigi G. et al., "Phase II Clinical Trial of RSD921 as a Local Anaesthetic in Patients Undergoing Venous Cannulation For Elective Treatment" 28th Annual ACCP Meet Abstract 32, pp 977	
Re	108.	Franciosi, Sonia et al. (2001) "pH-dependent blocking actions of three novel antiarrhythmic compounds on K ⁺ and Na ⁺ currents in rat ventricular myocytes" Eur J Pharm, 425:95-107	
Re	109.	Franciosi L et al. "Development and evaluation of a quality assessment instrument for clinical trial protocols." Pharmacologist 44(2):A160, 2002 (Abstract #98.1, Poster at XIV World Congress of Pharmacology, July 7-12, 2002, San Francisco, CA	
Re	110.	Franqueza, L. et al., (1998) "Effects of propafenone and 5-hydroxy-propafenone on hKv1.5 channels" Br J Pharm 125:969-978	
Re	111.	Friess, et al., (1961) "Central Activity Evoked in the Cat by Cis-Trans Isomers of 1,2-Aminocyclohexanol Derivatives" Toxicol. Appl. Pharmacol. 3:638-653	
Re	112.	Grant, (1998) "Mechanisms of Atrial Fibrillation and Action of Drugs Used in its Management", Am J Cardiol 82:43N-49N	
Re	113.	Halfpenny, Paul R. (1990) "Highly Selective <i>k</i> -Opioid Analgesics. 3. Synthesis and Structure-Activity Relationships of Novel N-[2-(1-Pyrrolidinyl)4- or -5-substituted-cyclohexyl]arylamide Derivatives" J Med Chem, 33:289-291	
Re	114.	Halfpenny, Paul R. et al., (1989) "Highly Selective <i>k</i> -Opioid Analgesics. 2. Synthesis and Structure-Activity Relationships of Novel N-[(2-Aminocyclohexyl)aryl]acetamide Derivatives" J Med Chem, 32:1620-1626	
EXAMINER: <i>Leberon Anderson</i>		DATE CONSIDERED: 3/18/05	
EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.			

*no date provided on 1449 or on reference (107)

Form PTO-1449		Docket Number 554792000401	Application Number 10/674,684
INFORMATION DISCLOSURE CITATION IN AN APPLICATION		Applicant Allan I. Bain et al.	
(Use several sheets if necessary)		Filing Date September 29, 2003	Group Art Unit 1626
		Mailing Date October 28, 2004	
115.	Hayes, ES. et al., (1997) "Actions of Arylpiperazines on Corpus Cavernosum Smooth Muscle <i>In Vitro</i> " Asia Pac J Pharmacol, 12:97-103		
116.	Hayes, ES. et al., (1997) "Direct Actions of Arylpiperazines on Rabbit and Human Corpus Cavernosum Smooth Muscle <i>In Vitro</i> " Asia Pac J Pharmacol, Abstract S15		
117.	Hayes, E. S. et al., (1996) "RSD992 Enhances Erection and Copulation in Rats and Erection in Primates" Int J Impotence Res, pp 189, (Abstract P24)		
118.	Hesketh, J., et al., "Safety of RSD1235 in a rabbit purkinje fiber model", (XIVth World Congress of Phar.: Meeting Abstracts: 22.12		
119.	Hesketh JC. and Fedida D. et al. "Ionic mechanisms of atrial fibrillation." In <u>Cardiac Drug Development Guide</u> , ed. Pugsley, M. Ch 9, pp163-174, Humana Press, NJ. 2003		
120.	International Search Report mailed on August 3, 1999, for PCT patent application no. PCT/CA99/00280, 5 pages		
121.	International Search Report mailed on July 12, 2004, for PCT patent application no. PCT/US03/34655 filed on October 31, 2003, 10 pages		
122.	Keefe, D. et al. (1981) "New Antiarrhythmic Drugs: Their Place in Therapy" Drugs 22:363-400		
123.	Kertesz, R. et al., "The Electrophysiological and Antiarrhythmic Actions of RSD Analogs of U50,488H in Rats" Proc west Pharmacol Soc ab. 9 pages		
124.	Lang, C. C. et al., (2000) "Clinical Evaluation of RSD921 As a Local Anaesthetic in Patients Undergoing Venous Cannulation for Elective Treatment" Clin Pharm & Therapeutics, pp 142		
125.	Lewis, et al., (1995) "Enzyme inhibition during the conversion of squalene to cholesterol", Steroids 60:475-483		
126.	Li, G-R. et al., (1996) "Adrenergic Modulation of Ultrarapid Delayed Rectifier K ⁺ current in Human Atrial Myocytes" Circ. Res.78:903-915		
127.	Malayev, A. A. et al., (1995) "Mechanism of Clofilium Block of the Human Kv1.5 Delayed Rectifier Potassium Channel" Mol Pharm 47:198-205		
128.	Martens, et al., (1989) "Einfache Synthese neuer anellierter Pyrrole", J. Synth. Org.		
EXAMINER: <i>Lebeun...</i>		DATE CONSIDERED: 3/18/05	
EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.			

*no date provided on 1449 or on reference (123)(118)

Form PTO-1449		Docket Number 554792000401	Application Number 10/674,684
INFORMATION DISCLOSURE CITATION IN AN APPLICATION		Applicant Allan I. Bain et al.	
(Use several sheets if necessary)		Filing Date September 29, 2003	Group Art Unit 1626
		Mailing Date October 28, 2004	
Chem. 12:965-967			
129.	Matyus, et al., (1997) "Antiarrhythmic Agents: Current Status and Perspective", Medicinal Research Reviews 17(5):427-451		
130.	McLarnon, J. et al., (1996) "Mixed Block of K and Na Currents By KC8851, A Structural of Tedisamil <i>In Vitro</i> and <i>In Vivo</i> Studies" BPS Proceedings 114P		
131.	Moorman, et al., (1986) "pK _a Does Not Predict pH Potentiation of Sodium Channel Blockade by Lidocaine and W6211 in Guinea Pig Ventricular Myocardium ¹ ", The Journal of Pharmacology and Experimental Therapeutics 238(1):159-166		
132.	Morisawa, et al., (1991) "Preparation of fluorocarbocycle nucleosides as antitumor agents", Chemical Abstracts 115(5):904-905, abstract no. 50215n		
133.	Nakahsima, H. et al., (2002) "Angiotensin II Type I Receptor Antagonist Prevents the Promotion of Atrial Fibrillation" PACE 24(Part II):698. Abstract 701		
134.	Nattel, (1998) "Experimental evidence for proarrhythmic mechanisms of antiarrhythmic drugs", Cardiovascular Research 37:567-577		
135.	Nattel, et al., (1998) "Effects of the novel antiarrhythmic agent azimilide on experimental atrial fibrillation and atrial electrophysiologic properties", Cardiovascular Research 37:627-635		
136.	Nattel, et al., (2001) "P2362: RSD1235: a novel antiarrhythmic agent with a unique electrophysiological profile that terminates AF in dogs", Eur. Heart J 22(Suppl):448 (Abstract P2362)		
137.	Nattel, S. et al., "The Role of Channel Opening in Transient Outward Current Block By Quinidine, Flecainide, and 4-Aminopyridine in Human Atrial Myocytes" K Channels II: Regulation and Block, Tu-Pos403		
138.	Nattel, S. et al., "RSD1235: a novel antiarrhythmic agent with a unique electrophysiological profile that terminates AF in dogs" Antiarrhythmic Agents, pg 448		
139.	Nishi, et al., (1985) "Studies on 2-Oxoquinoline Derivatives as Blood Platelet Aggregation Inhibitors. IV." Synthesis and Biological Activity of the Metabolites of 6-[4-(1-Cyclohexyl-1 H-5-tetrazolyl)butoxy]-2-oxo-1,2,3,4-tetrahydroquinoline (OPC-13013)", Chem. Pharm. Bull 33(3):1140-1147		
EXAMINER: <i>Lebeun</i>		DATE CONSIDERED: 3/18/05	
EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.			

sf- 1807564PTO/SB/ 08 (2-92)

Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

* no date provided on 1449 or on reference (138) (137)

Form PTO-1449		Docket Number 554792000401	Application Number 10/674,684
INFORMATION DISCLOSURE CITATION IN AN APPLICATION		Applicant Allan I. Bain et al.	
(Use several sheets if necessary)		Filing Date September 29, 2003	Group Art Unit 1626
		Mailing Date	October 28, 2004
Rb	140.	Nortran Arrhythmia Drug Demonstrates Oral Bioavailability. New Release Transmitted By CNN Newswire, June 21, 2001. 2 pages	
Rb	141.	Orth, et al., (1978) "Cyclopentane-1-amines" Chemical Abstracts 89(15):555, abstract no. 129113f	
Rb	142.	Orth, Peter et al., "The Novel AF Conversion Agent RSD1235 Preferentially Blocks a Late Component of the Human Heart (hH1) Na ⁺ Current Active During Repolarization" EP abstracts October 2003	
Rb	143.	Plouvier, B., "Synthesis and Structure Activity Relationships of a Series of 2-Aminocyclohexyl...as Potential Ischaemia Selective Ventricular Antiarrhythmics. BMPS 994 (2002)	
	144.	Pugsley and Goldin (1999) "Molecular analysis of the Na⁺ channel blocking actions of the novel class I antiarrhythmic" Br J Pharm, 127:9-18	
Rb	145.	Pugsley, M.K. et al., "A Characterization of the Antiarrhythmic and Electrophysiological Properties of RSD992, A Novel Arylpiperazine Drug" (XIVth World Congress of Pharmacology: Meeting Abstract 22.8) (2002)	
Rb	146.	Pugsley, M.K. et al., (1999) "Are the arrhythmias due to myocardial ischaemia and infarction dependent upon the sympathetic system?" Cardiol Res, 43:830-831	
	147.	Pugsley, M.K. et al., "Electropharmacology of two new class I agents" Heart and Stroke Annual	
Rb	148.	Pugsley, M.K. et al., (1998) "Sodium Channel-Blocking Properties of Spiradoline, a K Receptor Agonist, are Responsible for Its Antiarrhythmic Action in the Rat" J Cardiovas Pharmacol, 32:863-974	
Rf	149.	Ribeiro, W. et al., (2001) "Determination of RSD921 in human plasma by high-performance liquid chromatography-tandem mass spectrometry using tri-deuterated RSD921 as internal standard: application to a phase I clinical trial" J Mass Spectrom, 36:1133-1139	
	150.	Rich, T. C. et al. "Quinidine Block of the Human Cardiac hKv1.5 Channel in Inside-Out Patches" K Channels II: Regulation and Block, Tu-Pos404	
Rb	151.	Roden, et al., (1996) "The Cardiac Ion Channels: Relevance to Management of	
EXAMINER: <i>Deborah Anderson</i>		DATE CONSIDERED: 3/18/05	
EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.			

sf- 1807564PTO/SB/ 08 (2-92)

Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

* no date provided on 1449 or on reference (150)(147)

* no copy of reference provided, only order form from British Journal of Pharmacology.

Form PTO-1449		Docket Number 554792000401	Application Number 10/674,684
INFORMATION DISCLOSURE CITATION IN AN APPLICATION		Applicant Allan I. Bain et al.	
(Use several sheets if necessary)		Filing Date September 29, 2003	Group Art Unit 1626
		Mailing Date	October 28, 2004
Arrhythmias", Annu. Rev. Med. 47:135-148			
Rb	152.	Roy, D. et al., (2003) "RSD1235 Rapidly and Effectively Terminates Atrial Fibrillation" Eur Heart J.	
Rb	153.	Rynbrandt, Ronald H, et al., (1971) "Cis-1-[2-(p-Anisidinomethyl)cyclohexyl]piperidine and Related Compounds Oral Hypoglycemic Agents" J Med Chem, 14(10): 985-987	
Rb	154.	Sandro, L. et al., (1997) "Low pKa Predicts Antiarrhythmic Efficacy in a Series of Aminocyclohexyl Esters" J Mol Cell Cardiol.	
Rb	155.	Sanguinetti, M. C. (1992) "Modulation of Potassium Channels by Antiarrhythmic and Antihypertensive Drugs" Hypertension 19(3):228-236	
Rb	156.	Shiroshita-Takeshita A. et al. "Differential Efficacy of Drugs with Antioxidant Properties on Atrial Fibrillation Promotion by Atrial Tachycardia Remodeling in Dogs." Circulation 2003 in press, (accepted for presentation at AHA Scientific Sessions, November 8-12, 2003 Orlando, FL).	
Rb	157.	Singh, (1998) "Antiarrhythmic Drugs: A Reorientation in Light of Recent Developments in the Control of Disorders of Rhythm", Am J Cardiol 81(6A):3D-13D.	
Rb	158.	Singh, (2003) "Atrial Fibrillation: Epidemiologic Considerations and Rationale for Conversion and Maintenance of Sinus Rhythm", J. Cardiovasc. Pharmacol. Ther. 8(Suppl 1):S13-S26	
Rb	159.	Snyders, D. J. et al., (1993) "A Rapidly Activating and Slowly Inactivating Potassium Channel Cloned from Human Heart" J. Gen. Physiol. 101:513-542	
Rb	160.	Snyders, D. J. et al., (1995) "Determinants of Antiarrhythmic Drug Action Electrostatic and Hydrophobic Components of Block of the Human Cardiac hKv1.5 Channel" Circ. Res. 77 (3):575-583	
Rb	161.	Srilatha, B. et al., (1997) "Alterations in Rabbit Corpus Cavernosal Pharmacology By High Cholesterol Diet" Asia Par J Pharmacol, Abstract S15	
Rb	162.	Steinbeck, G. (1992) "Proarrhythmische Wirkungen von Antiarrhythmika-theoretische undKlinische Aspekte" Z Kardiol. 81: Suppl. 4, 139-143	
Rb	163.	Tong, V. et al., (2001) "Determination of an aryether antiarrhythmic and its N-dealkyl metabolite in rat plasma and hepatic microsomal incubates using liquid	
EXAMINER: <i>Lebeun Anderson</i>		DATE CONSIDERED: 3/18/05	
EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.			

Form PTO-1449		Docket Number 554792000401	Application Number 10/674,684
INFORMATION DISCLOSURE CITATION IN AN APPLICATION		Applicant Allan I. Bain et al.	
(Use several sheets if necessary)		Filing Date September 29, 2003	Group Art Unit 1626
		Mailing Date October 28, 2004	
		chromatography-tandem mass spectrometry" <i>J Chromatog B.</i> , 759:256-266	
RA	164.	Tong V. et al. (2001) "In vitro investigation of the hepatic extraction of RSD1070, a novel antiarrhythmic compound." <i>J Pharmacy & Pharmaceutical Sciences</i> , 4(1):15-23	
RA	165.	Valenzuela, C. et al. (1997) "Comparative effects of nonsedating histamine H ₁ receptor antagonists, ebastine and terfenadine, on human Kv1.5 channels" <i>Eur J Pharm</i> 326:257-263.	
RA	166.	Valenzuela, C. et al., (1997) "Effects of Ropivacaine on a Potassium Channel (hKv1.5) Cloned from Human Ventricle" <i>Anesthesiology</i> 86:718-728	
RA	167.	Walker, J. A. (2002) "Antiarrhythmic Drug Development - Illusion and Disillusion". <i>Drug Develop Res</i> 55:1-2	
RA	168.	Walker, M. L. et al., (1996) "Determination of an arylacetamide antiarrhythmic in rat blood and tissues using reversed-phase high-performance liquid chromatography" <i>J Chromatog B.</i> , 675:257-263	
RA	169.	Walker, M.L. et al., (1996) "Increased Electrophysiological Activity in Raised K and low pH Improves Antiarrhythmic efficacy for a group of morpholinocyclohexyl Derivatives". <i>BPS Proceedings</i> 118P	
	170.	Walker, Michael J.A. and Guppy, Leon J. "Targeting Ischemic Ventricular Arrhythmias" <i>Cardiac Drug Development</i> , pp 175-201	
RA	171.	Wang, Z. et al., (1995) "Effects of Flecainide, Quinidine, and 4-Aminopyridine on Transient Outward and Ultrarapid Delayed Rectifier Currents in Human Atrial Myocytes" <i>J Pharm Exp ther.</i> , 272(1):184-196	
RA	172.	Wang, Z. et al., (1993) "Sustained Depolarization-Induced Outward Current in Human Atrial Myocytes" <i>Circ. Res.</i> 73:1061-1076	
*	173.	Wat, J.Y.K. et al., "Effects of Arylbenzacetamides on Neuromuscular Preparation" <i>Proc West Pharmacol Soc</i> 19	
*	174.	Wolf, et al. (1998) "Impact of Atrial Fibrillation on Mortality Stroke, and Medical Costs" <i>Arch Intern Med</i> 158: 229-234	
*	175.	Wong, Judy et al., "Protein Binding Study of AA5, a New Antiarrhythmic Drug" <i>Poster Conference August</i>	
EXAMINER: <i>Robert J. Anderson</i>		DATE CONSIDERED: <i>3/18/05</i>	
EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.			

sf- 1807564PTO/SB/ 08 (2-92)

Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

* no date provided on 1449 or on reference (175)(173)(170)
 * no copy of reference provided, only order form from archives of internal medicine (174)

Form PTO-1449	Docket Number 554792000401	Application Number 10/674,684
INFORMATION DISCLOSURE CITATION IN AN APPLICATION	Applicant Allan I. Bain et al.	
(Use several sheets if necessary)	Filing Date September 29, 2003	Group Art Unit 1626
	Mailing Date October 28, 2004	

	176.	Wong, L. et al., "Capillary Electrophoresis Assay to Assess In Vitro Metabolic Stability of Novel Compounds in Human Liver Microsomes"
Rb	177.	Yeola, S. W. et al., (1996) "Molecular Analysis of a Binding Site for Quinidine in a Human Cardiac Delayed Rectifier K ⁺ Channel" Circ. Res. 78(6): 1105-1114
Rb	178.	Yong, et al., (1999) "RSD1000: A novel antiarrhythmic agent with increased potency under acidic and high-potassium conditions" J. Pharm. Exp. Ther. 289(1):236-244
Rb	179.	Yong, S.L. et al., (1996) "RSD1000: A Novel Antiarrhythmic Agent with an Improved Therapeutic Index" BPS Proceedings 119P
Rb	180.	Yong, S.L. et al., (1996) "SAR Evidence that Antiarrhythmic Activity is Unrelated to Opioid Kappa Agonist Activity" BPS Proceedings 117P
Rb	181.	Yong SL et al. (2000) "A Comparison of Four Chemically-Related K ⁺ Channel Blockers in Isolated Rat Ventricular Myocytes." Proceedings of the Western Pharmacology Society, vol. 43, p121 abstract
Ra	182.	Zhang, et al., (1997) "Inhibition of [³ H]-U69593 binding and the cardiac effects of U50, 488H by calcium channel blockers in the rat heart" Brit. J. Pharmacol. 120:827-832
Rb	183.	Zolotoy, Alexander B. et al., (2003) "Physicochemical Determinants for Drug Induced Blockade of HERG Potassium Channels: Effect of Charge and Charge Shielding" Curr Med Chem 1(3): 1-17

EXAMINER:


Robert Anderson

DATE CONSIDERED:

3/18/05

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

* no date on 1449 or on reference

FORM PTO-1449 (REV. 7-80)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 480102.403C2	APPLICATION NO. 10/674,684
 INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		APPLICANTS Allen I. Bain et al.	
		FILING DATE September 29, 2003	GROUP ART UNIT 1626

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
DB	AA	6,210,809	04/03/01	Okutomi et al.	428	546	
BA	AB	6,214,810	04/10/01	Fermini et al.	514	75	
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						


FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
					YES	NO
	AK					
	AL					
	AM					
	AN					
	AO					

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

	AP	
	AQ	
	AR	


EXAMINER



DATE CONSIDERED

3/18/05

* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

FORM PTO-1449
(REV. 7-80)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
480102.403C2APPLICATION NO.
10/674,684INFORMATION DISCLOSURE STATEMENT
(Use several sheets if necessary)

APPLICANTS

Allen I. Bain et al.

FILING DATE

September 29, 2003

GROUP ART UNIT

1626

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
<i>PS</i>	AA	6,214,809	04/10/01	Fermini et al.	514	75	
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
					YES	NO
	AK					
	AL					
	AM					
	AN					
	AO					

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

	AP		
	AQ		
	AR		

EXAMINER

Lebecca Anderson

DATE CONSIDERED

3/18/05

* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).